Trilaciclib Interaction Studies Found Little Change in Oral Midazolam Exposure

An enzyme-interaction concern identified in laboratory work did not translate into a large midazolam exposure change in this human protocol.

What the supplied source reports

Prospective fixed-sequence phase I studies evaluated trilaciclib with several probe medicines in healthy volunteers. The geometric mean ratio for midazolam exposure with versus without trilaciclib was 1.065, with a ninety-percent confidence interval of 0.984–1.154. Metformin exposure changed more substantially, illustrating substrate-specific results.

Limits of the evidence

The findings concern the doses, schedules and oral probe administration studied. They do not establish absence of every interaction during cancer treatment or equal effects in organ impairment. A pharmacokinetic comparison also does not directly measure procedural sedation or driving performance.

Implications for forensic interpretation

For expert interpretation, identify the direction of the interaction and the measured endpoint. Laboratory inhibition, predicted interaction and observed clinical exposure are separate evidence steps. The paper provides direct human midazolam data under defined conditions without proving that all co-medications or patient settings behave similarly.

Source and related reading

Source reviewed: Pharmacokinetic Drug Drug Interaction Studies Between Trilaciclib and Midazolam Metformin Rifampin I (PMC9338108). Forensic applications above are interpretive analysis of the supplied publication.